Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Biotech Industry Analysis

UpdatedJan 07, 2026
DataAggregated Company Financials
Companies50
  • 7D-0.7%
  • 3M-0.8%
  • 1Y-7.9%
  • YTD0.5%

In the last week, the Biotech industry is flat overall, with Vitrolife standing out by going down 4.2%. As for the longer term, the industry has declined 7.9% in the last year. Looking forward, earnings are forecast to grow by 30% annually.

Industry Valuation and Performance

Has the Swedish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 08 Jan 2026SEK 206.7bSEK 38.1b-SEK 556,348,257.0433.8x-371.5x5.4x
Sat, 06 Dec 2025SEK 209.4bSEK 38.1b-SEK 603,799,266.0431.5x-346.9x5.5x
Mon, 03 Nov 2025SEK 206.4bSEK 37.3b-SEK 1,210,338,400.4338.8x-170.5x5.5x
Wed, 01 Oct 2025SEK 199.2bSEK 36.4bSEK 3.0b31.3x65.8x5.5x
Fri, 29 Aug 2025SEK 204.0bSEK 36.0bSEK 2.9b33.9x71.4x5.7x
Sun, 27 Jul 2025SEK 192.9bSEK 35.9bSEK 2.8b28.7x69.1x5.4x
Tue, 24 Jun 2025SEK 178.9bSEK 35.2bSEK 2.2b28.1x80.3x5.1x
Thu, 22 May 2025SEK 195.2bSEK 33.9bSEK 1.2b34x162.4x5.8x
Sat, 19 Apr 2025SEK 175.2bSEK 33.7bSEK 758.0m29x231.2x5.2x
Mon, 17 Mar 2025SEK 196.7bSEK 33.7bSEK 579.2m33.2x339.6x5.8x
Wed, 12 Feb 2025SEK 217.0bSEK 33.7bSEK 360.6m52.9x601.7x6.4x
Fri, 10 Jan 2025SEK 217.8bSEK 33.0b-SEK 4,418,458,844.01150.4x-49.3x6.6x
Sun, 08 Dec 2024SEK 214.0bSEK 33.0b-SEK 4,445,850,513.32146.4x-48.1x6.5x
Tue, 05 Nov 2024SEK 218.1bSEK 33.2b-SEK 4,482,242,588.44136.1x-48.7x6.6x
Thu, 03 Oct 2024SEK 210.4bSEK 31.4b-SEK 5,523,741,940.7849.5x-38.1x6.7x
Sat, 31 Aug 2024SEK 216.4bSEK 31.4b-SEK 5,530,209,354.7351.1x-39.1x6.9x
Mon, 29 Jul 2024SEK 205.1bSEK 31.4b-SEK 5,422,714,425.0246.9x-37.8x6.5x
Wed, 26 Jun 2024SEK 196.7bSEK 30.6b-SEK 5,517,165,724.6539.2x-35.7x6.4x
Fri, 24 May 2024SEK 192.4bSEK 30.6b-SEK 5,401,683,980.7139.6x-35.6x6.3x
Sun, 21 Apr 2024SEK 178.5bSEK 29.8b-SEK 5,265,765,392.2366.1x-33.9x6x
Tue, 19 Mar 2024SEK 184.5bSEK 29.8b-SEK 5,637,407,911.1159.3x-32.7x6.2x
Thu, 15 Feb 2024SEK 175.6bSEK 29.6b-SEK 5,684,331,437.9662.6x-30.9x5.9x
Sat, 13 Jan 2024SEK 190.3bSEK 28.7b-SEK 1,198,820,921.0060.5x-158.8x6.6x
Mon, 11 Dec 2023SEK 169.9bSEK 28.7b-SEK 1,200,221,950.0058.4x-141.6x5.9x
Wed, 08 Nov 2023SEK 157.7bSEK 28.6b-SEK 1,293,048,329.0049.4x-122x5.5x
Fri, 06 Oct 2023SEK 157.5bSEK 27.4b-SEK 2,017,186,235.0048.4x-78.1x5.8x
Sun, 03 Sep 2023SEK 155.4bSEK 27.3b-SEK 1,924,351,833.0052.5x-80.8x5.7x
Tue, 01 Aug 2023SEK 158.4bSEK 27.5b-SEK 1,533,460,949.0054.5x-103.3x5.8x
Thu, 29 Jun 2023SEK 157.1bSEK 26.4b-SEK 1,317,540,523.0045x-119.3x6x
Sat, 27 May 2023SEK 170.7bSEK 26.3b-SEK 1,253,213,583.0046.3x-136.2x6.5x
Mon, 24 Apr 2023SEK 173.8bSEK 25.5b-SEK 2,076,198,392.0039.7x-83.7x6.8x
Wed, 22 Mar 2023SEK 164.5bSEK 25.4b-SEK 2,030,305,555.0037.5x-81x6.5x
Fri, 17 Feb 2023SEK 172.0bSEK 25.3b-SEK 1,661,189,878.0027.1x-103.5x6.8x
Sun, 15 Jan 2023SEK 173.3bSEK 23.8b-SEK 1,844,159,459.0031.6x-94x7.3x
Price to Earnings Ratio

-94x


Total Market Cap: SEK 173.3bTotal Earnings: -SEK 1,844,159,459.00Total Revenue: SEK 23.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Biotech Industry Price to Earnings3Y Average -45.6x202420252026
Current Industry PE
  • Investors are pessimistic on the Swedish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 6.1x is higher than the industry's current PS ratio of 5.4x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Revenues for these companies have grown 17% per year.
  • This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market0.026%
Healthcare-1.62%
Biotech-0.67%
Biotech-0.67%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 337.601.4%
+SEK 1.7b		6.0%PE8950.5x
BIOA B BioArcticSEK 329.005.9%
+SEK 1.6b		59.7%PE29.2x
VITR VitrolifeSEK 139.301.7%
+SEK 311.5m		-34.1%PE42.9x
VICO Vicore Pharma HoldingSEK 12.208.0%
+SEK 253.4m		24.1%PS404x
BINV BioInvent InternationalSEK 31.457.0%
+SEK 134.9m		-12.4%PS8.5x

Latest News

SOBI
SEK 337.60
Swedish Orphan Biovitrum
7D
1.4%
1Y
6.0%
VICO
SEK 12.20
Vicore Pharma Holding
7D
8.0%
1Y
24.1%
HNSA
SEK 32.64
Hansa Biopharma
7D
-5.0%
1Y
-6.6%

HNSA: Buy Initiation And FDA Filing Will Shape Upside Potential

Analysts have adjusted their price view on Hansa Biopharma from SEK 143 to SEK 111, citing updated assumptions on discount rates, revenue growth, profit margins and future P/E, along with fresh coverage that includes a new SEK 100 target from Street research. Analyst Commentary Bullish analysts see the recent SEK 100 price target as a constructive marker for where Hansa Biopharma could trade if the company executes in line with their assumptions on revenue, margins and future P/E.
BINV
SEK 31.45
BioInvent International
7D
7.0%
1Y
-12.4%
EGTX
SEK 4.95
Egetis Therapeutics
7D
-7.3%
1Y
-25.0%
CRNO B
SEK 6.90
Cereno Scientific
7D
-1.3%
1Y
35.0%
BIOA B
SEK 329.00
BioArctic
7D
5.9%
1Y
59.7%

BIOA B Future Long Term Margin Upside Will Not Offset Demand Risks

Analysts have modestly raised their price target on BioArctic to SEK 230 (from SEK 230 previously), reflecting slightly lower perceived risk and a substantially improved long term profit margin outlook, despite marginally weaker revenue growth assumptions and a lower projected future P/E multiple. What's in the News Leqembi, developed by BioArctic and Eisai, has been included in China’s new Commercial Insurance Innovative Drug List.
ONCO
SEK 4.58
Oncopeptides
7D
-4.7%
1Y
191.7%

ONCO: Improved Profitability And NK Cell Platform Will Drive Long-Term Upside

Analysts have raised their price target on Oncopeptides from approximately SEK 4.50 to SEK 5.50 per share, citing expectations of stronger long term profitability, supported by higher projected profit margins and a lower future price to earnings multiple, despite slightly tempered revenue growth assumptions and a modestly higher discount rate. What's in the News Panel of leading multiple myeloma experts publishes clinical recommendations in Annals of Hematology on optimal use of Pepaxti (melflufen), reinforcing its role as an important option for relapsed, refractory multiple myeloma, including elderly and high risk patients, with a manageable safety profile (company announcement).
VITR
SEK 139.30
Vitrolife
7D
1.7%
1Y
-34.1%

VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential

Analysts have slightly reduced their price target on Vitrolife, trimming fair value by SEK 4.75 to SEK 188.75, as modestly higher long term growth assumptions are offset by a small downgrade to profitability and a lower expected valuation multiple. What's in the News Vitrolife plans to record a SEK 5.4 billion goodwill impairment in the fourth quarter of 2025 related to the Igenomix acquisition (company announcement).
SYNACT
SEK 21.55
SynAct Pharma
7D
-4.6%
1Y
92.4%
BONEX
SEK 183.70
Bonesupport Holding
7D
-2.3%
1Y
-53.5%

BONEX: De Novo Pathway Shift Will Support Strong Future Market Position

Analysts have modestly raised their price target on Bonesupport Holding, citing a slightly lower discount rate and improved visibility into sustaining approximately 38 percent revenue growth and robust 31 percent profit margins. Together, these factors support a fair value of SEK 391.20 per share.
DMYD B
SEK 11.52
Diamyd Medical
7D
2.3%
1Y
-35.7%
CANTA
SEK 4.48
Cantargia
7D
7.0%
1Y
167.0%
DVYSR
SEK 110.00
Devyser Diagnostics
7D
-3.7%
1Y
-7.2%
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%
XSPRAY
SEK 29.30
Xspray Pharma
7D
-6.8%
1Y
-19.5%